Sparsentan FDA approval date

The FDA approved Sparsentan (Filspari) on 17 Feb 2023.

FDA approval date
17 Feb 2023

Drug identity checked against registry records

Also recorded as Filspari; RE-021

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-02-17DaySparsentanFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA216403", "applicant_as_listed_by_fda": "TRAVERE", "brand_names": ["FILSPARI"], "active_ingredients": ["SPARSENTAN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230217", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026